<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461589</url>
  </required_header>
  <id_info>
    <org_study_id>NN9535-4191</org_study_id>
    <secondary_id>2014-003196-39</secondary_id>
    <secondary_id>U1111-1159-4923</secondary_id>
    <nct_id>NCT02461589</nct_id>
  </id_info>
  <brief_title>Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes</brief_title>
  <official_title>Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted globally. The aim of this trial is to investigate dose-finding of
      semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects
      with type 2 diabetes
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2015</start_date>
  <completion_date type="Actual">October 13, 2016</completion_date>
  <primary_completion_date type="Actual">October 13, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c (Glycosylated Haemoglobin)</measure>
    <time_frame>Week 0, week 26</time_frame>
    <description>Estimated mean change from baseline in HbA1c at week 26. The data were analysed for the &quot;on-treatment until rescue medication&quot; observation period which includes observations recorded at or after date of first dose of trial product and not after the last dose of trial product plus the 7-day visit window or date of initiation of rescue therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>Estimated mean change from baseline in FPG at week 26. The data were analysed for the &quot;on-treatment until rescue medication&quot; observation period which includes observations recorded at or after date of first dose of trial product and not after the last dose of trial product plus the 7-day visit window or date of initiation of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight Change</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>The data were analysed for the &quot;on-treatment until rescue medication&quot; observation period which includes observations recorded at or after date of first dose of trial product and not after the last dose of trial product plus the 7-day visit window or date of initiation of rescue therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic and Diastolic Blood Pressure</measure>
    <time_frame>Week 0, Week 26</time_frame>
    <description>The data were analysed for the &quot;on-treatment until rescue medication&quot; observation period which includes observations recorded at or after date of first dose of trial product and not after the last dose of trial product plus the 7-day visit window or date of initiation of rescue therapy.</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">706</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Semaglutide 0.05 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 0.3 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 50 µL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide 0.05/0.1 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 0.3/0.6 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 50/100 µL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide 0.05/0.1/0.2 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 0.3/0.6/1.2 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 50/100/200 µL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide 0.05/0.1/0.2/0.3 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide 0.3/0.6/1.2/1.8 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 50/100/200/300 µL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide flexible escalation from 0.05 mg/day to 0.3 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.</description>
    <arm_group_label>Semaglutide 0.05 mg/day</arm_group_label>
    <arm_group_label>Semaglutide 0.05/0.1 mg/day</arm_group_label>
    <arm_group_label>Semaglutide 0.05/0.1/0.2 mg/day</arm_group_label>
    <arm_group_label>Semaglutide 0.05/0.1/0.2/0.3 mg/day</arm_group_label>
    <arm_group_label>Semaglutide flexible escalation from 0.05 mg/day to 0.3 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.</description>
    <arm_group_label>Liraglutide 0.3 mg/day</arm_group_label>
    <arm_group_label>Liraglutide 0.3/0.6 mg/day</arm_group_label>
    <arm_group_label>Liraglutide 0.3/0.6/1.2 mg/day</arm_group_label>
    <arm_group_label>Liraglutide 0.3/0.6/1.2/1.8 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Administered subcutaneously ( s.c., under the skin) once daily.</description>
    <arm_group_label>Placebo 50 µL</arm_group_label>
    <arm_group_label>Placebo 50/100 µL</arm_group_label>
    <arm_group_label>Placebo 50/100/200 µL</arm_group_label>
    <arm_group_label>Placebo 50/100/200/300 µL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age at least 18 years at the time of signing informed consent.

          -  Subjects should be on stable diabetes treatment consisting of diet and exercise with
             or without metformin (at least 1500 mg daily or maximum tolerated dose documented in
             the patient medical record) for at least 90 days prior to screening

          -  HbA1c (glycosylated haemoglobin): 53-86 mmol/mol (7.0-10.0%) (both inclusive)

          -  BMI: 25.0 - 40.0 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  Simultaneous participation in any other clinical trial of an investigational medicinal
             product

          -  Female who is pregnant, breast-feeding or intends to become pregnant or is of
             child-bearing potential and not using adequate contraceptive methods throughout the
             trial including the 7 weeks follow-up period (adequate contraceptive measures as
             required by local regulation or practice). Germany: Only highly effective methods of
             birth control are accepted (i.e. one that results in less than 1% per year failure
             rate when used consistently and correctly such as implants, injectables, combined oral
             contraceptives, some intrauterine device), or sexual abstinence or vasectomised
             partner. United Kingdom: Adequate contraceptive measures are defined as established
             use of oral, injected or implanted hormonal methods of contraception, placement of an
             intrauterine device or intrauterine system, barrier methods of contraception (condom
             or occlusive cap with spermicidal foam/gel/film/cream/suppository), female
             sterilisation, male sterilisation (where partner is sole partner of subject), or true
             abstinence (when in line with preferred and usual lifestyle)

          -  Treatment with any medication for the indication of diabetes or obesity other than
             stated in the inclusion criteria in a period of 90 days before screening (an exception
             is short-term insulin treatment for acute illnesses for a total of below or equal to
             14 days)

          -  Anticipated initiation or change in concomitant medications (for more than 14
             consecutive days or on an frequent basis) known to affect weight or glucose metabolism
             (e.g. orlistat, thyroid hormones, corticosteroids)

          -  History of pancreatitis (acute or chronic)

          -  Screening calcitonin above or equal to 50 ng/L

          -  Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary
             Thyroid Carcinoma (MTC)

          -  Severe to moderate renal impairment defined as GFR, estimated below 60 ml/min/1.73 m^2
             as per CKD-EPI (Chronic Kidney Disease Epidemiology)

          -  Within the past 180 days before screening any of the following: Myocardial infarction,
             stroke or hospitalisation for unstable angina and/or transient ischemic attack

          -  Currently planned coronary, carotid or peripheral artery revascularisation

          -  Patients presently classified as being in New York Heart Association (NYHA) Class III
             or IV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Van Nuys</city>
        <state>California</state>
        <zip>91405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33183</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201-2477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017-3464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458-2937</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70461-4231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Buckley</city>
        <state>Michigan</state>
        <zip>49620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Belzoni</city>
        <state>Mississippi</state>
        <zip>39038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Elkhorn</city>
        <state>Nebraska</state>
        <zip>68022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hopewell Junction</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <zip>43015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040-6815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330-3737</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Downingtown</city>
        <state>Pennsylvania</state>
        <zip>19335-2620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Smithfield</city>
        <state>Pennsylvania</state>
        <zip>15478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hodges</city>
        <state>South Carolina</state>
        <zip>29653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Indian Land</city>
        <state>South Carolina</state>
        <zip>29707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620-7352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119-4806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012-4637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Missouri City</city>
        <state>Texas</state>
        <zip>77459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Riverton</city>
        <state>Utah</state>
        <zip>84065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216-1557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint Stefan</city>
        <zip>8511</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3K 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1G 1A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8K 3P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Strathroy</city>
        <state>Ontario</state>
        <zip>N7G 1Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7T 2P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pointe Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Benesov</city>
        <zip>25601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Liberec</city>
        <zip>46001</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nachod</city>
        <zip>54701</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Plzeň</city>
        <zip>301 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Police nad Metuji</city>
        <zip>54954</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 46</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Trutnov</city>
        <zip>541 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Eisenach</city>
        <zip>99817</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Friedrichsthal</city>
        <zip>66299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22607</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pohlheim</city>
        <zip>35415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rehlingen-Siersburg</city>
        <zip>66780</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint Ingbert</city>
        <zip>66386</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70378</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sulzbach-Rosenberg</city>
        <zip>92237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Klang, Selangor</city>
        <zip>41200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kota Bharu</city>
        <zip>15586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Penang</city>
        <zip>10450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seremban</city>
        <zip>70300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seri Manjung</city>
        <zip>32040</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dzerzhinskiy</city>
        <zip>140091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kazan</city>
        <zip>420073</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191119</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Syktyvkar</city>
        <zip>167981</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Voronezh</city>
        <zip>394018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zajecar</city>
        <zip>19000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1812</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Midrand</city>
        <state>Gauteng</state>
        <zip>1685</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4450</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Middleburg</city>
        <state>Mpumalanga</state>
        <zip>1055</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Basingstoke</city>
        <zip>RG24 9GT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT16 1RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bexhill-on-Sea</city>
        <zip>TN39 4SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Blackburn</city>
        <zip>BB2 1AX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chesterfield, Derbyshire</city>
        <zip>S40 4AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Devon</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Harrogate, North Yorkshire</city>
        <zip>HG2 7SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hinckley</city>
        <zip>LE10 2SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <zip>PL8 8DQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sidcup</city>
        <zip>DA14 6LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Malaysia</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <results_first_submitted>December 21, 2017</results_first_submitted>
  <results_first_submitted_qc>December 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2018</results_first_posted>
  <disposition_first_submitted>September 22, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>September 22, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 28, 2017</disposition_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at 139 sites in 10 countries as follows:
Austria: 3 sites; Canada: 8 sites; Czech Republic: 9 sites; Germany:
7 sites; Malaysia: 5 sites; Russian Federation: 7 sites; Serbia: 9 sites; South Africa: 7 sites; United Kingdom: 13 sites; United States: 71 sites.</recruitment_details>
      <pre_assignment_details>Of the 706 subjects randomised in the trial, 705 were exposed to trial products and 1 randomised subject withdrew prior to exposure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Semaglutide 0.05 mg/Day</title>
          <description>Participants received semaglutide 0.05 mg subcutaneous (sc) injection once daily for 26 weeks. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="P2">
          <title>Semaglutide 0.1 mg/Day</title>
          <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="P3">
          <title>Semaglutide 0.2 mg/Day</title>
          <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks and then semaglutide 0.2 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="P4">
          <title>Semaglutide 0.3 mg/Day</title>
          <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks followed by 0.2 mg once daily for next 4 weeks and then semaglutide 0.3 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="P5">
          <title>Liraglutide 0.3 mg/Day</title>
          <description>Participants received liraglutide 0.3 mg sc injection once daily for 26 weeks. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="P6">
          <title>Liraglutide 0.6 mg/Day</title>
          <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="P7">
          <title>Liraglutide 1.2 mg/Day</title>
          <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily for next 4 weeks and then liraglutide 1.2 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="P8">
          <title>Liraglutide 1.8 mg/Day</title>
          <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily for next 4 weeks followed by liraglutide 1.2 mg once daily for next 4 weeks and then liraglutide 1.8 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="P9">
          <title>Placebo</title>
          <description>Participants received placebo (the volume matched the volume used for the specific dose of semaglutide or liraglutide) sc injection once daily upto 26 weeks. Placebo injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="P10">
          <title>Semaglutide Flexible</title>
          <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks followed by 0.2 mg once daily for next 4 weeks and then semaglutide 0.3 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals. Participants were allowed to follow a more flexible dose-escalation regimen based on gastrointestinal tolerability. Semaglutide dose levels could be reduced in participants with poor gastrointestinal tolerability depending on investigator’s assessment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="64"/>
                <participants group_id="P6" count="64"/>
                <participants group_id="P7" count="64"/>
                <participants group_id="P8" count="65"/>
                <participants group_id="P9" count="129"/>
                <participants group_id="P10" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="65"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="64"/>
                <participants group_id="P6" count="64"/>
                <participants group_id="P7" count="64"/>
                <participants group_id="P8" count="65"/>
                <participants group_id="P9" count="129"/>
                <participants group_id="P10" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="58"/>
                <participants group_id="P5" count="62"/>
                <participants group_id="P6" count="61"/>
                <participants group_id="P7" count="58"/>
                <participants group_id="P8" count="60"/>
                <participants group_id="P9" count="123"/>
                <participants group_id="P10" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing follow-up information</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal from trial before exposure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on the full analysis set (FAS) which included all randomised subjects who had received at least 1 dose of either semaglutide, liraglutide or placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>Semaglutide 0.05 mg/Day</title>
          <description>Participants received semaglutide 0.05 mg subcutaneous (sc) injection once daily for 26 weeks. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="B2">
          <title>Semaglutide 0.1 mg/Day</title>
          <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="B3">
          <title>Semaglutide 0.2 mg/Day</title>
          <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks and then semaglutide 0.2 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="B4">
          <title>Semaglutide 0.3 mg/Day</title>
          <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks followed by 0.2 mg once daily for next 4 weeks and then semaglutide 0.3 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="B5">
          <title>Liraglutide 0.3 mg/Day</title>
          <description>Participants received liraglutide 0.3 mg sc injection once daily for 26 weeks. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="B6">
          <title>Liraglutide 0.6 mg/Day</title>
          <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="B7">
          <title>Liraglutide 1.2 mg/Day</title>
          <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily for next 4 weeks and then liraglutide 1.2 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="B8">
          <title>Liraglutide 1.8 mg/Day</title>
          <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily for next 4 weeks followed by liraglutide 1.2 mg once daily for next 4 weeks and then liraglutide 1.8 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="B9">
          <title>Placebo</title>
          <description>Participants received placebo (the volume matched the volume used for the specific dose of semaglutide or liraglutide) sc injection once daily upto 26 weeks. Placebo injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="B10">
          <title>Semaglutide Flexible</title>
          <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks followed by 0.2 mg once daily for next 4 weeks and then semaglutide 0.3 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals. Participants were allowed to follow a more flexible dose-escalation regimen based on gastrointestinal tolerability. Semaglutide dose levels could be reduced in participants with poor gastrointestinal tolerability depending on investigator’s assessment.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="65"/>
            <count group_id="B4" value="63"/>
            <count group_id="B5" value="64"/>
            <count group_id="B6" value="64"/>
            <count group_id="B7" value="64"/>
            <count group_id="B8" value="65"/>
            <count group_id="B9" value="129"/>
            <count group_id="B10" value="64"/>
            <count group_id="B11" value="705"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.53" spread="9.8"/>
                    <measurement group_id="B2" value="57.51" spread="10.0"/>
                    <measurement group_id="B3" value="58.37" spread="9.58"/>
                    <measurement group_id="B4" value="54.76" spread="9.66"/>
                    <measurement group_id="B5" value="57.20" spread="10.78"/>
                    <measurement group_id="B6" value="59.45" spread="9.77"/>
                    <measurement group_id="B7" value="53.73" spread="11.35"/>
                    <measurement group_id="B8" value="55.82" spread="9.19"/>
                    <measurement group_id="B9" value="57.08" spread="9.25"/>
                    <measurement group_id="B10" value="54.81" spread="9.70"/>
                    <measurement group_id="B11" value="56.67" spread="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="32"/>
                    <measurement group_id="B9" value="57"/>
                    <measurement group_id="B10" value="28"/>
                    <measurement group_id="B11" value="326"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="34"/>
                    <measurement group_id="B8" value="33"/>
                    <measurement group_id="B9" value="72"/>
                    <measurement group_id="B10" value="36"/>
                    <measurement group_id="B11" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c (glycosylated haemoglobin)</title>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.87" spread="0.71"/>
                    <measurement group_id="B2" value="7.91" spread="0.83"/>
                    <measurement group_id="B3" value="7.96" spread="0.82"/>
                    <measurement group_id="B4" value="8.23" spread="0.80"/>
                    <measurement group_id="B5" value="8.06" spread="0.86"/>
                    <measurement group_id="B6" value="8.12" spread="0.81"/>
                    <measurement group_id="B7" value="8.14" spread="0.87"/>
                    <measurement group_id="B8" value="8.07" spread="0.85"/>
                    <measurement group_id="B9" value="8.12" spread="0.87"/>
                    <measurement group_id="B10" value="8.10" spread="0.91"/>
                    <measurement group_id="B11" value="8.06" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.26" spread="2.60"/>
                    <measurement group_id="B2" value="8.97" spread="2.22"/>
                    <measurement group_id="B3" value="9.20" spread="2.28"/>
                    <measurement group_id="B4" value="9.67" spread="2.56"/>
                    <measurement group_id="B5" value="9.32" spread="2.54"/>
                    <measurement group_id="B6" value="9.34" spread="2.33"/>
                    <measurement group_id="B7" value="9.91" spread="2.70"/>
                    <measurement group_id="B8" value="9.18" spread="2.45"/>
                    <measurement group_id="B9" value="9.67" spread="2.98"/>
                    <measurement group_id="B10" value="9.82" spread="2.66"/>
                    <measurement group_id="B11" value="9.45" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.44" spread="18.27"/>
                    <measurement group_id="B2" value="92.40" spread="17.20"/>
                    <measurement group_id="B3" value="98.07" spread="17.92"/>
                    <measurement group_id="B4" value="94.82" spread="17.84"/>
                    <measurement group_id="B5" value="92.25" spread="17.48"/>
                    <measurement group_id="B6" value="92.68" spread="16.46"/>
                    <measurement group_id="B7" value="96.67" spread="18.28"/>
                    <measurement group_id="B8" value="93.40" spread="19.34"/>
                    <measurement group_id="B9" value="93.98" spread="17.75"/>
                    <measurement group_id="B10" value="95.29" spread="15.43"/>
                    <measurement group_id="B11" value="94.28" spread="17.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133.70" spread="15.14"/>
                    <measurement group_id="B2" value="130.97" spread="14.92"/>
                    <measurement group_id="B3" value="131.34" spread="12.55"/>
                    <measurement group_id="B4" value="132.08" spread="11.69"/>
                    <measurement group_id="B5" value="134.02" spread="11.30"/>
                    <measurement group_id="B6" value="132.41" spread="12.37"/>
                    <measurement group_id="B7" value="134.20" spread="12.73"/>
                    <measurement group_id="B8" value="131.02" spread="11.86"/>
                    <measurement group_id="B9" value="132.17" spread="14.26"/>
                    <measurement group_id="B10" value="132.70" spread="12.74"/>
                    <measurement group_id="B11" value="132.43" spread="13.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.06" spread="8.90"/>
                    <measurement group_id="B2" value="79.71" spread="8.56"/>
                    <measurement group_id="B3" value="80.48" spread="8.87"/>
                    <measurement group_id="B4" value="81.41" spread="8.05"/>
                    <measurement group_id="B5" value="81.83" spread="6.98"/>
                    <measurement group_id="B6" value="81.28" spread="6.90"/>
                    <measurement group_id="B7" value="82.98" spread="6.94"/>
                    <measurement group_id="B8" value="80.66" spread="7.62"/>
                    <measurement group_id="B9" value="80.98" spread="8.00"/>
                    <measurement group_id="B10" value="81.89" spread="8.40"/>
                    <measurement group_id="B11" value="81.11" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c (Glycosylated Haemoglobin)</title>
        <description>Estimated mean change from baseline in HbA1c at week 26. The data were analysed for the &quot;on-treatment until rescue medication&quot; observation period which includes observations recorded at or after date of first dose of trial product and not after the last dose of trial product plus the 7-day visit window or date of initiation of rescue therapy.</description>
        <time_frame>Week 0, week 26</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg subcutaneous (sc) injection once daily for 26 weeks. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks and then semaglutide 0.2 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks followed by 0.2 mg once daily for next 4 weeks and then semaglutide 0.3 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 0.3 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 26 weeks. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O6">
            <title>Liraglutide 0.6 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O7">
            <title>Liraglutide 1.2 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily for next 4 weeks and then liraglutide 1.2 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 1.8 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily for next 4 weeks followed by liraglutide 1.2 mg once daily for next 4 weeks and then liraglutide 1.8 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>Participants received placebo (the volume matched the volume used for the specific dose of semaglutide or liraglutide) sc injection once daily upto 26 weeks. Placebo injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O10">
            <title>Semaglutide Flexible</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks followed by 0.2 mg once daily for next 4 weeks and then semaglutide 0.3 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals. Participants were allowed to follow a more flexible dose-escalation regimen based on gastrointestinal tolerability. Semaglutide dose levels could be reduced in participants with poor gastrointestinal tolerability depending on investigator’s assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c (Glycosylated Haemoglobin)</title>
          <description>Estimated mean change from baseline in HbA1c at week 26. The data were analysed for the &quot;on-treatment until rescue medication&quot; observation period which includes observations recorded at or after date of first dose of trial product and not after the last dose of trial product plus the 7-day visit window or date of initiation of rescue therapy.</description>
          <population>Full analysis set</population>
          <units>percentage of glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="129"/>
                <count group_id="O10" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="0.85"/>
                    <measurement group_id="O2" value="-1.30" spread="1.03"/>
                    <measurement group_id="O3" value="-1.65" spread="0.79"/>
                    <measurement group_id="O4" value="-1.96" spread="0.95"/>
                    <measurement group_id="O5" value="-0.50" spread="0.93"/>
                    <measurement group_id="O6" value="-0.88" spread="0.90"/>
                    <measurement group_id="O7" value="-0.86" spread="0.92"/>
                    <measurement group_id="O8" value="-1.32" spread="0.78"/>
                    <measurement group_id="O9" value="-0.05" spread="0.90"/>
                    <measurement group_id="O10" value="-1.72" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Treatment difference</param_type>
            <param_value>-1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>-0.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Treatment difference</param_type>
            <param_value>-1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>-1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Treatment difference</param_type>
            <param_value>-1.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.95</ci_lower_limit>
            <ci_upper_limit>-1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Treatment difference</param_type>
            <param_value>-1.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.12</ci_lower_limit>
            <ci_upper_limit>-1.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG)</title>
        <description>Estimated mean change from baseline in FPG at week 26. The data were analysed for the &quot;on-treatment until rescue medication&quot; observation period which includes observations recorded at or after date of first dose of trial product and not after the last dose of trial product plus the 7-day visit window or date of initiation of rescue therapy.</description>
        <time_frame>Week 0, Week 26</time_frame>
        <population>Full analyses set. For &quot;Semaglutide flexible arm&quot;, data was available only for 63 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg subcutaneous (sc) injection once daily for 26 weeks. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks and then semaglutide 0.2 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks followed by 0.2 mg once daily for next 4 weeks and then semaglutide 0.3 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 0.3 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 26 weeks. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O6">
            <title>Liraglutide 0.6 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O7">
            <title>Liraglutide 1.2 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily for next 4 weeks and then liraglutide 1.2 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 1.8 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily for next 4 weeks followed by liraglutide 1.2 mg once daily for next 4 weeks and then liraglutide 1.8 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>Participants received placebo (the volume matched the volume used for the specific dose of semaglutide or liraglutide) sc injection once daily upto 26 weeks. Placebo injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O10">
            <title>Semaglutide Flexible</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks followed by 0.2 mg once daily for next 4 weeks and then semaglutide 0.3 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals. Participants were allowed to follow a more flexible dose-escalation regimen based on gastrointestinal tolerability. Semaglutide dose levels could be reduced in participants with poor gastrointestinal tolerability depending on investigator’s assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG)</title>
          <description>Estimated mean change from baseline in FPG at week 26. The data were analysed for the &quot;on-treatment until rescue medication&quot; observation period which includes observations recorded at or after date of first dose of trial product and not after the last dose of trial product plus the 7-day visit window or date of initiation of rescue therapy.</description>
          <population>Full analyses set. For &quot;Semaglutide flexible arm&quot;, data was available only for 63 subjects.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="129"/>
                <count group_id="O10" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.09" spread="1.96"/>
                    <measurement group_id="O2" value="-2.08" spread="2.23"/>
                    <measurement group_id="O3" value="-2.64" spread="2.07"/>
                    <measurement group_id="O4" value="-3.53" spread="2.20"/>
                    <measurement group_id="O5" value="-1.33" spread="2.06"/>
                    <measurement group_id="O6" value="-1.56" spread="1.74"/>
                    <measurement group_id="O7" value="-1.51" spread="2.41"/>
                    <measurement group_id="O8" value="-1.92" spread="2.34"/>
                    <measurement group_id="O9" value="-0.54" spread="2.45"/>
                    <measurement group_id="O10" value="-3.40" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight Change</title>
        <description>The data were analysed for the &quot;on-treatment until rescue medication&quot; observation period which includes observations recorded at or after date of first dose of trial product and not after the last dose of trial product plus the 7-day visit window or date of initiation of rescue therapy.</description>
        <time_frame>Week 0, Week 26</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg subcutaneous (sc) injection once daily for 26 weeks. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks and then semaglutide 0.2 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks followed by 0.2 mg once daily for next 4 weeks and then semaglutide 0.3 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 0.3 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 26 weeks. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O6">
            <title>Liraglutide 0.6 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O7">
            <title>Liraglutide 1.2 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily for next 4 weeks and then liraglutide 1.2 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 1.8 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily for next 4 weeks followed by liraglutide 1.2 mg once daily for next 4 weeks and then liraglutide 1.8 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>Participants received placebo (the volume matched the volume used for the specific dose of semaglutide or liraglutide) sc injection once daily upto 26 weeks. Placebo injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O10">
            <title>Semaglutide Flexible</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks followed by 0.2 mg once daily for next 4 weeks and then semaglutide 0.3 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals. Participants were allowed to follow a more flexible dose-escalation regimen based on gastrointestinal tolerability. Semaglutide dose levels could be reduced in participants with poor gastrointestinal tolerability depending on investigator’s assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight Change</title>
          <description>The data were analysed for the &quot;on-treatment until rescue medication&quot; observation period which includes observations recorded at or after date of first dose of trial product and not after the last dose of trial product plus the 7-day visit window or date of initiation of rescue therapy.</description>
          <population>Full analysis set</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="129"/>
                <count group_id="O10" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.75" spread="2.82"/>
                    <measurement group_id="O2" value="-4.36" spread="4.24"/>
                    <measurement group_id="O3" value="-6.70" spread="4.57"/>
                    <measurement group_id="O4" value="-8.23" spread="5.34"/>
                    <measurement group_id="O5" value="-1.48" spread="3.06"/>
                    <measurement group_id="O6" value="-1.81" spread="3.06"/>
                    <measurement group_id="O7" value="-1.78" spread="3.41"/>
                    <measurement group_id="O8" value="-3.68" spread="4.26"/>
                    <measurement group_id="O9" value="-1.22" spread="3.42"/>
                    <measurement group_id="O10" value="-6.60" spread="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic and Diastolic Blood Pressure</title>
        <description>The data were analysed for the &quot;on-treatment until rescue medication&quot; observation period which includes observations recorded at or after date of first dose of trial product and not after the last dose of trial product plus the 7-day visit window or date of initiation of rescue therapy.</description>
        <time_frame>Week 0, Week 26</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg subcutaneous (sc) injection once daily for 26 weeks. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks and then semaglutide 0.2 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg/Day</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks followed by 0.2 mg once daily for next 4 weeks and then semaglutide 0.3 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O5">
            <title>Liraglutide 0.3 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 26 weeks. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O6">
            <title>Liraglutide 0.6 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O7">
            <title>Liraglutide 1.2 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily for next 4 weeks and then liraglutide 1.2 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 1.8 mg/Day</title>
            <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily for next 4 weeks followed by liraglutide 1.2 mg once daily for next 4 weeks and then liraglutide 1.8 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O9">
            <title>Placebo</title>
            <description>Participants received placebo (the volume matched the volume used for the specific dose of semaglutide or liraglutide) sc injection once daily upto 26 weeks. Placebo injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
          </group>
          <group group_id="O10">
            <title>Semaglutide Flexible</title>
            <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks followed by 0.2 mg once daily for next 4 weeks and then semaglutide 0.3 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals. Participants were allowed to follow a more flexible dose-escalation regimen based on gastrointestinal tolerability. Semaglutide dose levels could be reduced in participants with poor gastrointestinal tolerability depending on investigator’s assessment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic and Diastolic Blood Pressure</title>
          <description>The data were analysed for the &quot;on-treatment until rescue medication&quot; observation period which includes observations recorded at or after date of first dose of trial product and not after the last dose of trial product plus the 7-day visit window or date of initiation of rescue therapy.</description>
          <population>Full analysis set</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="63"/>
                <count group_id="O5" value="64"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="64"/>
                <count group_id="O8" value="65"/>
                <count group_id="O9" value="129"/>
                <count group_id="O10" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolicblood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.74" spread="12.30"/>
                    <measurement group_id="O2" value="-2.77" spread="13.21"/>
                    <measurement group_id="O3" value="-4.25" spread="12.24"/>
                    <measurement group_id="O4" value="-9.85" spread="11.58"/>
                    <measurement group_id="O5" value="-3.77" spread="9.79"/>
                    <measurement group_id="O6" value="-3.20" spread="10.89"/>
                    <measurement group_id="O7" value="-4.69" spread="12.73"/>
                    <measurement group_id="O8" value="-2.99" spread="11.94"/>
                    <measurement group_id="O9" value="-2.34" spread="11.40"/>
                    <measurement group_id="O10" value="-6.62" spread="14.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="8.78"/>
                    <measurement group_id="O2" value="0.66" spread="8.26"/>
                    <measurement group_id="O3" value="-1.62" spread="9.38"/>
                    <measurement group_id="O4" value="-4.02" spread="8.56"/>
                    <measurement group_id="O5" value="-1.77" spread="7.37"/>
                    <measurement group_id="O6" value="-1.89" spread="8.20"/>
                    <measurement group_id="O7" value="-0.60" spread="6.78"/>
                    <measurement group_id="O8" value="0.63" spread="8.13"/>
                    <measurement group_id="O9" value="-0.61" spread="8.50"/>
                    <measurement group_id="O10" value="-1.69" spread="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline up to week 33.</time_frame>
      <desc>Safety analysis set (SAS) included all randomised subjects exposed to at least one dose of trial product. Subjects in the SAS would contribute to the evaluation “as treated”. Treatment-emergent adverse events (TEAEs) were defined as events recorded from the first dose of trial product and until completion of the post-treatment follow-up visit (7 weeks).</desc>
      <group_list>
        <group group_id="E1">
          <title>Semaglutide 0.05 mg/Day</title>
          <description>Participants received semaglutide 0.05 mg subcutaneous (sc) injection once daily for 26 weeks. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="E2">
          <title>Semaglutide 0.1 mg/Day</title>
          <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="E3">
          <title>Semaglutide 0.2 mg/Day</title>
          <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks and then semaglutide 0.2 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="E4">
          <title>Semaglutide 0.3 mg/Day</title>
          <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks followed by 0.2 mg once daily for next 4 weeks and then semaglutide 0.3 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="E5">
          <title>Liraglutide 0.3 mg/Day</title>
          <description>Participants received liraglutide 0.3 mg sc injection once daily for 26 weeks. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="E6">
          <title>Liraglutide 0.6 mg/Day</title>
          <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="E7">
          <title>Liraglutide 1.2 mg/Day</title>
          <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily for next 4 weeks and then liraglutide 1.2 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="E8">
          <title>Liraglutide 1.8 mg/Day</title>
          <description>Participants received liraglutide 0.3 mg sc injection once daily for 4 weeks followed by liraglutide 0.6 mg once daily for next 4 weeks followed by liraglutide 1.2 mg once daily for next 4 weeks and then liraglutide 1.8 mg once daily upto week 26. Liraglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="E9">
          <title>Placebo</title>
          <description>Participants received placebo (the volume matched the volume used for the specific dose of semaglutide or liraglutide) sc injection once daily upto 26 weeks. Placebo injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals.</description>
        </group>
        <group group_id="E10">
          <title>Semaglutide Flexible</title>
          <description>Participants received semaglutide 0.05 mg sc injection once daily for 4 weeks followed by semaglutide 0.1 mg once daily for next 4 weeks followed by 0.2 mg once daily for next 4 weeks and then semaglutide 0.3 mg once daily upto week 26. Semaglutide injection was administered in the thigh, abdomen, or upper arm, preferably around the same time of the day irrespective of meals. Participants were allowed to follow a more flexible dose-escalation regimen based on gastrointestinal tolerability. Semaglutide dose levels could be reduced in participants with poor gastrointestinal tolerability depending on investigator’s assessment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Epiploic appendagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Escherichia pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Cystoscopy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Spinal meningioma benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Endarterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Vascular graft</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="65"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="64"/>
                <counts group_id="E7" subjects_affected="35" subjects_at_risk="64"/>
                <counts group_id="E8" subjects_affected="35" subjects_at_risk="65"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" subjects_affected="44" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E8" events="13" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="7" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="7" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="8" subjects_affected="6" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="11" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="6" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="65"/>
                <counts group_id="E4" events="29" subjects_affected="16" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="9" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E7" events="8" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E8" events="16" subjects_affected="8" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="22" subjects_affected="11" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="9" subjects_affected="6" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="5" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E2" events="20" subjects_affected="12" subjects_at_risk="63"/>
                <counts group_id="E3" events="22" subjects_affected="14" subjects_at_risk="65"/>
                <counts group_id="E4" events="22" subjects_affected="16" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E6" events="11" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E7" events="11" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E8" events="18" subjects_affected="13" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="35" subjects_affected="25" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E2" events="13" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="10" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="8" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="8" subjects_affected="6" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="4" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" events="7" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="11" subjects_affected="10" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="6" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="9" subjects_affected="9" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="5" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="8" subjects_affected="6" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E2" events="30" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E3" events="13" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E4" events="11" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="11" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E7" events="16" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E8" events="8" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="14" subjects_affected="7" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Registry (GCR, 1452)</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

